Laurie Glimcher Steps Down as Dana-Farber CEO, Benjamin Ebert Named Successor

Glimcher's departure follows her pivotal decision to sever ties with Brigham & Women's and build a new hospital with Beth Israel Deaconess.

Glimcher, 73, initiated her departure to make way for new leadership after eight years as CEO.
Her tenure saw the launch of a $1.68 billion hospital project and a $2 billion fundraising campaign.
Dr. Benjamin Ebert, chair of Dana-Farber’s medical oncology department, will take over on Oct. 1.
Ebert's appointment ensures continuity in the ambitious hospital project with Beth Israel Deaconess.
Glimcher will return to immunology research and spend more time with her family.